01.27.25 -- Comparing In-House Vs. Outsourced Manufacturing Strategies For CGTs

Explore advanced AAV production platforms that enhance efficiency, scalability, and compliance, paving the way for safe and accessible gene therapies.

Review the importance of alternative approaches to viral vector production and the benefits of intensified adherent cell culture for improving efficiency, reducing costs, and accelerating development.

Manufacturing mRNA products is a complex and challenging process that requires careful consideration at each stage. Learn more about the challenges and intricacies involved.

As the landscape of CAR T-cell therapies evolves, these treatments are becoming more precise in targeting cancer cells and overcoming production challenges, and are poised to revolutionize oncology.

Partner with a specialized CDMO early in your CGT development to ensure a streamlined path from discovery to successful commercialization, avoiding costly pitfalls and delays.

Advance your gene therapy program with expert support for IND submission, including GLP toxicology, biodistribution studies, and tailored CMC services.

Create a simple, modular path to cGMP manufacturing that minimizes risk. Explore a strategic approach for early-stage development and how it can propel therapies to the clinic and the market.

For any biotherapeutic in development today, a critical element in achieving commercialization is reducing manufacturing risk.

Mathias Kahl, Director of Process Development, shares insights on overcoming challenges in AAV and LV viral vector manufacturing.